Transkaryotic Therapies
-
ETFs and Mutual Funds: Why not both?
Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...
Our Products
Services
Upcoming Events
Conferences
-
Morningstar Investment Conference
June 12-14, 2013
Chicago, IL
Conference hashtag: #MIC25 -
Morningstar ETF Invest Conference
Oct. 2-4, 2013
Chicago, IL
Conference hashtag: #ETFInvest
Webinars
-
Real Assets to the Rescue
Tuesday, April 9
11:00 a.m. ET | 10:00 a.m. CT -
The Hunt for Income
Tuesday, January 29
11:00 a.m. ET | 10:00 a.m. CT -
Introduction to ETF Managed Portfolios
Monday, December 10
4:00 p.m. ET | 3:00 p.m. CT -
Using ETFs for Income
Aired on Tuesday, June 12 - Archive
